成人血友病A中FVIII药代动力学与VWF及FVIII清除遗传修饰因子的关联
研究在44例成人中重度血友病A患者中评估FVIII药代动力学,检测VWF抗原、VWF前肽、VWF:FVIII结合活性及CLEC4M、SCARA5、STAB2、ABO等基因变异。发现VWF:FVIII结合活性及VWF清除遗传决定因素(如CLEC4M rs868875和VNTR)是FVIII药代动力学的重要贡献者。
要点
- VWF:Ag、VWFpp和VWF:FVIIIB与FVIII半衰期正相关,与清除负相关。
- CLEC4M rs868875杂合子较参考等位基因纯合子FVIII清除增加。
- CLEC4M 5-VNTR频率在FVIII清除最慢四分位患者中降低。
核心结论
- VWF-FVIII结合活性及VWF清除的遗传决定因素是成人血友病A患者FVIII药代动力学的重要贡献者。
研究设计与样本
- 在44例年龄18-61岁的中重度血友病A成人患者中进行FVIII药代动力学评估。
- 检测VWF:Ag、VWFpp、VWFpp/VWF:Ag及VWF:FVIII结合活性。
- 对VWF修饰位点CLEC4M、SCARA5、STAB2、ABO及VWF基因D'D3 FVIII结合区域进行基因分型。
主要发现
- VWF:Ag、VWFpp和VWF:FVIIIB与FVIII半衰期正相关,与FVIII清除负相关。
- VWFpp/VWF:Ag与FVIII半衰期负相关,与FVIII清除正相关。
- VWFpp/VWF:Ag与FVIII半衰期的相关性在非O型患者中强于O型患者。
- CLEC4M rs868875杂合子患者较参考等位基因纯合子FVIII清除增加。
- CLEC4M VNTR等位基因与FVIII清除速率相关;FVIII清除最慢四分位患者中CLEC4M 5-VNTR频率降低。
临床怎么用
- 成人血友病A患者FVIII药代动力学评估可考虑结合VWF:FVIII结合活性及CLEC4M等VWF清除相关基因变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Factor VIII (FVIII) pharmacokinetics (PK) in adult hemophilia A populations are highly variable and have been previously determined to be influenced by von Willebrand factor:antigen (VWF:Ag), ABO blood group, and age. However, additional genetic determinants of FVIII PK are largely unknown. OBJECTIVES: The contribution of VWF clearance, VWF-FVIII-binding activity, and genetic variants in VWF clearance receptors to FVIII PK in adult patients were assessed. METHODS: FVIII PK assessment was performed in 44 adult subjects (age 18-61 years) with moderate or severe hemophilia A. VWF:Ag, VWF propeptide (VWFpp), VWFpp/VWF:Ag, and VWF:FVIII binding activity were measured. The VWF modifying loci CLEC4M, SCARA5, STAB2, and ABO, and the D'D3 FVIII-binding region of the VWF gene were genotyped. RESULTS: VWF:Ag, VWFpp, and VWF:FVIIIB positively correlated with FVIII half-life and negatively correlated with FVIII clearance. VWFpp/VWF:Ag negatively correlated with FVIII half-life and positively correlated with FVIII clearance. The correlation between VWFpp/VWF:Ag and FVIII half-life was stronger for type non-O patients than for type O patients, suggesting that slower VWF clearance increases FVIII half-life. Patients heterozygous for the CLEC4M rs868875 variant had increased FVIII clearance when compared with individuals homozygous for the reference allele. The CLEC4M variable number of tandem repeat (VNTR) alleles were also associated with the rate of FVIII clearance. When compared with the quartile of patients with the fastest FVIII clearance, the quartile of patients with the slowest FVIII clearance had a decreased frequency of the CLEC4M 5-VNTR. CONCLUSIONS: VWF-FVIII binding activity and genetic determinants of VWF clearance are important contributors to FVIII pharmacokinetics in adult patients.
引用
- Ogiwara K, Swystun LL, Paine AS, et al. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population. J Thromb Haemost. 2020. PMID: 33219619. doi:10.1111/jth.15183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。